Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
(BEAT) $1.30 --MC $10 m--near FDA approval ...very cheap medical device company with attractive Product near FDA approval expected during Q4 ...
HeartBeam submits heart attack diagnostic platform for FDA 510(k) clearance
https://www.massdevice.com/heartbeam-heart-attack-diagnostic-fda-510k-clearance/
Anticipated Milestones:
HeartBeam AIMI Platform (for the Emergency Department)
Development of FDA-Ready Product - Q2 2022
FDA Study Completed – Q3 2022
FDA Submission – Q3 2022
FDA Clearance – Q4 2022
Limited Market Release – Q4 2022
Product Launch – Q1 2023
HeartBeam AIMIGo Device (for telehealth)
Development of FDA-Ready Product – Q4 2022
FDA Study Completed – Q4 2022
FDA Submission – Q4 2022
FDA Clearance - Q1 2023
Limited Market Release – Q2 2023
Product Launch – Q3 2023
INM up 35% only 700k O/S
INM $8 has only 700k O/S could explode like PIXY today which has similar O/S
INM next PIXY both have similar O/S
(INM) $9.10 ..only 700k O/S another hot RS gem ..could explode like PIXY
(NLSP) $0.69 --BIG data readout in 19 days ..this dirt cheap biotech has 10 bagger potential if the drug is effective
$ARDS 1.52 ..MC $27 m..2x BIG Phase 3 Drugs near readout expected during next 2 months ..extremely underpriced low floater here
"The company is on track to report top-line data from the AR-301 Phase 3 study in ventilator associated pneumonia (VAP) and the AR-501 Phase 2a study in cystic fibrosis during the second half of 2022," commented Vu Truong, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals. "We believe these data readouts will be significant and transformative milestones for the Company. In addition, we completed the manufacturing of the clinical trial supplies and launched the global Phase 3 trial of AR-320."
(ABEO) MC $23 m -BIG Phase 3 results expected in the coming ...Shares Out 6 million
"Topline data from the Phase 3 VIITALâ„¢ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 "
EYEN $1.96 up 22% ---BIG Phase 3 readout coming within days
(ARDS) $1.46 --has 2x Big Phase 3 Drugs and low valuation of $26 million ,this could be the next big runner like RVPH
Continued enrollment in the Company's Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis remains on track to report top-line data from this study in 2H 2022.
EYEN,RVPH & ABEO all Phase 3 gems , EYEN & ABEO about to release Phase 3 data in September while RVPH expected in mid 2023 ...EYEN looks more attractive at this time with 3x Phase 3 Products
ABEO $4.25 .big Phase 3 data around the corner
(ABEO) MC $24 million ....O/S 6 mil ...
"Topline data from the Phase 3 VIITALâ„¢ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 "
ABEO $4.25 next to explode like NERV with big Phase 3 data around the corner
(ABEO) MC $24 million ....O/S 6 mil ...
"Topline data from the Phase 3 VIITALâ„¢ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 "
(ABEO) MC $24 m / O/S 6 mil / Phase 3 results in September
"Topline data from the Phase 3 VIITALâ„¢ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 "
(VAXX) $2.45 --Best Covid Vaccine ? Company about to release Phase 3 results if positive then stock could be a multibagger
"The Phase 3 heterologous boost study evaluating UB-612 against COVID-19 in subjects who have received primary immunization from mRNA, adenovirus vector, or inactivated viral vaccines is ongoing. Vaxxinity expects a topline readout in the second half of 2022, and if successful, these data will support global marketing authorization applications."
Vaxxinity looks to pioneer the next revolution in pharma
https://www.pharmavoice.com/news/vaxxinity-to-pioneer-the-next-revolution/617229/
RVPH not RVPX
(EDRY) $17 --PE 1 --Float 300k shares--MC $54 million --Book Value $34.50 per share
(APTX) 0.63 Halted -likely to release Phase 2b results lets hope for positive outcome
$COHN now $13 there are only 600k shrs on ther float with volume this one likely going parabolic
(COHN) $11.90 --Float 600k --MC $20 million --Book Value $35 per share ..maybe next MEGL here which went from $10 to $200+ within days
(COHN) $11.90 --Float 600k --MC $20 million --Book Value $35 per share
(COHN) $11.80 --Float 600k --MC $20 million --Book Value $35 per share = next HKD ???
APTX $0.60-- Cash $1.40 per Shr + 3x Big Drugs in Phase 2 with first readout expected during August
"Company expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August"